We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accenture Announces Acquisition of Life Sciences Company ESP
Read MoreHide Full Article
Accenture plc (ACN - Free Report) yesterday announced that it is going to acquire Cork, Ireland-based life sciences company, Enterprise System Partners (“ESP”). Upon closure, ESP will join Accenture Industry X.0. Financial terms of the deal were kept under wraps.
Founded in 2003, ESP provides consulting and manufacturing services to the life sciences industry. It is the latest of the many buyouts that Accenture has made to expand Accenture Industry X.0 in North America and Europe. These include hardware engineering firm Mindtribe, embedded software company Pillar Technology and design consultancy designaffairs.
Shares of Accenture have gained 16.1% year to date, outperforming 14.1% growth recorded by the industry it belongs to.
How Will Accenture Benefit?
The combination of Accenture Industry X.0’s capabilities and ESP’s manufacturing solutions is expected to enable Accenture expand its life sciences client base. It will enable Accenture’s clients to attain a flexible, efficient and cost-effective production process with the help of engineering and product lifecycle management, advanced analytics and artificial intelligence.
This in turn should boost the company’s Products segment that includes the Life Sciences industry group, and serves medical technology, pharmaceutical and biotechnology companies. The segment performed well in the last reported quarter, with revenues of $2.93 billion, increasing 8% year over year on a reported basis and 10% in local currency.
Zacks Rank & Stocks to Consider
Currently, Accenture carries a Zacks Rank #3 (Hold).
The long-term expected EPS (three to five years) growth rate for Omnicom, Robert Half and Automatic Data Processing is 6.9%, 8.4% and 12.8%, respectively.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Accenture Announces Acquisition of Life Sciences Company ESP
Accenture plc (ACN - Free Report) yesterday announced that it is going to acquire Cork, Ireland-based life sciences company, Enterprise System Partners (“ESP”). Upon closure, ESP will join Accenture Industry X.0. Financial terms of the deal were kept under wraps.
Founded in 2003, ESP provides consulting and manufacturing services to the life sciences industry. It is the latest of the many buyouts that Accenture has made to expand Accenture Industry X.0 in North America and Europe. These include hardware engineering firm Mindtribe, embedded software company Pillar Technology and design consultancy designaffairs.
Shares of Accenture have gained 16.1% year to date, outperforming 14.1% growth recorded by the industry it belongs to.
How Will Accenture Benefit?
The combination of Accenture Industry X.0’s capabilities and ESP’s manufacturing solutions is expected to enable Accenture expand its life sciences client base. It will enable Accenture’s clients to attain a flexible, efficient and cost-effective production process with the help of engineering and product lifecycle management, advanced analytics and artificial intelligence.
Accenture PLC Revenue (TTM)
Accenture PLC Revenue (TTM) | Accenture PLC Quote
This in turn should boost the company’s Products segment that includes the Life Sciences industry group, and serves medical technology, pharmaceutical and biotechnology companies. The segment performed well in the last reported quarter, with revenues of $2.93 billion, increasing 8% year over year on a reported basis and 10% in local currency.
Zacks Rank & Stocks to Consider
Currently, Accenture carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Business Services sector are Omnicom (OMC - Free Report) , Robert Half (RHI - Free Report) and Automatic Data Processing (ADP - Free Report) . While Robert Half sports a Zacks Rank #1 (Strong Buy), Omnicom and Automatic Data Processing carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The long-term expected EPS (three to five years) growth rate for Omnicom, Robert Half and Automatic Data Processing is 6.9%, 8.4% and 12.8%, respectively.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>